Vectura loses CFO after 11 years

VECTURA sees its chief financial officer Anne Hyland step down after 11 years in the post, to be succeeded by her understudy the financial controller Paul Oliver.

Hyland (pictured) is currently CFO, board member and company secretary for the business and helped list it onto the London Stock Exchange. Vectura provides therapies focussed on treating respiratory illnesses such as asthma.

Hyland was also pivotal in creating the company’s new venture in China, Tianjin Kinnovata Pharmaceuitcal and will continue to have involvement with that subsidiary.

Prior to Vectura she worked at British-based biotechnology business Celltech as director of corporate finance following its merger with Medeva where she was UK finance director. She began her career at KPMG where she worked for seven years, latterly as audit manager.

Hyland will be succeeded by the current financial controller Paul Oliver who is promoted to the role of CFO, company secretary and will have a seat on the board. ACCA-qualified Oliver has been with the company for seven years when he joined as FC.

Jack Cashman, chairman of Vectura, said: “On behalf of the board, I thank Anne for her considerable contribution to the transformation of Vectura over the last 11 years, most recently her central role in the establishment of Kinnovata.

“We are fortunate and pleased to be able to appoint Paul Oliver, a well-qualified internal successor to Anne, and look forward to working with Paul on Vectura’s continued success.”